Refine by
Prosthesis Articles & Analysis: Older
39 news found
A research team in Zurich, Switzerland has presented results from an in vitro study showing that photodisinfection achieved >99.99% eradication (4-7 log10 kill) of the key pathogens in biofilms associated with implantable joint infections, with no reported regrowth. These results were presented at the recent Swiss Society for Microbiology (SSM) Annual Congress 2022 in Lausanne, Switzerland. ...
As interventional cardiologist Zakaria Jalal explained to France3, “with time and healing, the components of the prosthesis will be digested by the body, the patient will eventually carry very few foreign bodies within his ...
12-Month Primary Endpoint Data Suggest OpRegen is Well Tolerated with an Acceptable Safety Profile Preliminary Evidence of Visual Function and Outer Retinal Structure Improvements Observed in Cohort 4 Patients with GA and Impaired Vision Data Reported at 2022 ARVO Meeting by Allen C. Ho, M.D., FACS Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage ...
Expansion of Pipeline Into a Third Neuronal Cell Type Builds on Existing Capabilities Intellectual Property Has Been Filed Covering Composition and Methods for Generating Auditory Neuronal Progenitors Hearing Loss Afflicts More Than 5% of the Population; More Than 430 Million People Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company ...
Earlier receipt of a prosthesis is associated with reduced spending in the 12 months post-amputation of approximately $25,000 compared with not receiving a prosthesis. The results of this study suggest that not providing or delaying the provision of a prosthesis increases costs by about 25%. iFIT can help facilitate fitting patients soon ...
However, we look forward to continuing the study with the next cohort as well as recruiting patients for our FDA IDE study and reporting more results during 2022,” Anteris CEO Wayne Paterson said. Naidu et al. Measuring TAVR Prosthesis Gradient Immediately Post-Procedure May Underestimate its Significance. ...
Conclusions: It is important that patients who would benefit from a lower limb prosthesis obtain one as soon as they are medically stable. Early fitting may provide a psychological boost to patients’ motivation, further promoting their overall health. ...
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announces the completion of investigations on its prostheses. Following the occurrence of a quality issue affecting some of its prostheses, ...
ByCarmat
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure,announces that it has voluntarilysuspended, on a temporary basis, theimplants of its Aeson® artificial heart. Following the occurrence ...
ByCarmat
This patient reduced their volume within a month period of time using the iFIT transtibial prosthesis. The iFIT system relieves swelling and shapes the limb quickly. ...
Puzzle Medical Devices Inc. is enthusiastic to partner with Patent Attorney C. Scott Talbot from Cooley LLP as it continues to grow its patent portfolio. Cooley LLP is the largest medical technology patent team in the US. Scott has more than two decades of experience in the medical technology industry, including with prosthetic heart valves, heart valve repair, orthopedic surgery, stents, blood ...
This new version includes certain improvements in the prosthesis and the wearable system based on clinical experience gained in the PIVOTAL study. ...
ByCarmat
We will also continue to execute our strong clinical plan, in particular the EFICAS study that should start in Q2 2021, but also a post-market clinical follow-up of 95 implanted patients, which will have a significant impact on the adoption momentum of our prosthesis. Given its unique features demonstrated in clinical trials to date, Aeson® introduces a new way of treating ...
ByCarmat
Labostera was founded in year 2005, they are experienced in ENT surgical products including surgical voice prosthesis, other surgical, ENT implants and equipment. APrevent cooperates with Labostera to expand market and sell APrevent® VOIS to Lithuania. ...
BioAesthetics Corporation today announced a clinical study of its nipple reconstruction graft will be performed at Stanford Medicine beginning in 2021. The BioAesthetics® NACgraft™ biologic matrix is a decellularized skin allograft of the human nipple-areolar complex (NAC) intended to replace the NAC when lost due to mastectomy or other procedure. BioAesthetics hopes the NACgraft will ...
With attractive tax incentives and our special financing option, the timing to purchase an Ortis system cannot get better: 1. Covid-19 Payment Deferment Program By financing your equipment purchase through our banking partners, you can take advantage of a special financing option: $0 down payment $0 payment for the first 6 months Simply put, you can acquire this technology for only $0 ...
BioAesthetics Corporation today announced that it has significantly surpassed its Series A funding goal of $2.5 million, further advancing its inaugural product — the nipple-areolar complex (NAC) graft, or NACgraftTM, for patients who are undergoing breast reconstruction following breast cancer and mastectomy — to clinical use. BioAesthetics’ Series A was led by a personal ...
This exceptional TAR system includes the Hintermann Series H3 (H3) 3-piece, mobile-bearing TAR prosthesis – time-tested globally for over 20 years with consistent, successful results and the Hintermann Series H2 (H2) 2-piece, semi-constrained TAR prosthesis. ...
” About the CUSTOMFLEX® ARTIFICIALIRIS The CUSTOMFLEX® ARTIFICIALIRIS is a foldable iris prosthesis, custom made for each individual patient, replicating the natural appearance of the patient’s eye. ...
Novostia aims at improvin g the quality of life of people suffering from heart valve disease, especially children and young patients, providing them with a unique, durable, anticoagulant-free and silent heart valve prosthesis. “This grant, together with our recent financing round of CHF 6.5 million, will accelerate the development of our technology toward the first in ...